In this episode of the Oncology Brothers podcast, we were joined by Dr. Toni Choueiri from Dana-Farber Cancer Institute to discuss key abstracts from ASCO 2024 in the field of Genitourinary Oncology. The discussion covered various studies and updates, including the EV302 study with Enfortumab Vedotin in combination with Pembrolizumab, which has been a new standard of care regimen for advanced urothelial carcinoma, since its last presentation at ESMO 2024, but here we discussed patient-reported outcomes from this study. The potential role of ctDNA was discussed, mainly using as a biomarker in bladder cancer, and real world data on how to treat advanced RCC was also highlighted.
EV-302: Patient reported outcomes from EV+Pembro vs. Platinum based chemo in mUC
KIM-1: Biomarker analysis in IMmotion010 in pts with RCC
Real world evidence from the IMDC: favorable vs. very favorable mRCC
PSMAfore: Health-related QoL and pain in taxane naïve pts with mCRPC
The conversation delved into the evolving paradigm in PSMA-targeted therapies for advanced prostate cancer, particularly focusing on health-related quality of life and pain outcomes. The discussion emphasized the significance of tailored therapies for favorable risk profiles in metastatic RCC, as well as the potential use of chemo with nivolumab in lymph node-only disease.
Overall, the episode provided valuable insights into the latest updates and studies from ASCO 2024 in the field of Genitourinary Oncology, showcasing the importance of patient outcomes, biomarkers, and personalized treatment approaches in improving cancer care. Tune in to our podcast for more discussions on oncology updates across different cancer types.
